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Abstract
Background: The purpose of our study was to compare differences in the prognosis of breast cancer (BC) patients
at high (H) risk or intermediate slightly (IS) increased risk based on family history and those without a family history
of BC, and to evaluate whether ten-year overall survival can be considered a good indicator of BRCA1 gene
mutation.
Methods: We classified 5923 breast cancer patients registered between 1988 and 2006 at the Department of
Oncology and Haematology in Modena, Italy, into one of three different risk categories according to Modena
criteria. One thousand eleven patients at H and IS increased risk were tested for BRCA1/2 mutations. The overall
survival (OS) and disease free survival (DFS) were the study end-points.
Results: Eighty BRCA1 carriers were identified. A statistically significantly better prognosis was observed for patients
belonging to the H risk category with respect to women in the IS and sporadic groups (82% vs.75% vs.73%,
respectively; p < 0.0001). Comparing only BRCA1 carriers with BRCA-negative and sporadic BC (77% vs.77% vs.73%,
respectively; p < 0.001) an advantage in OS was seen.
Conclusions: Patients belonging to a population with a high probability of being BRCA1 carriers had a better
prognosis than those with sporadic BC. Considering these results, women who previously had BC and had survived
ten years could be selected for BRCA1 analysis among family members at high risk of hereditary BC during genetic
counselling. Since only 30% of patients with a high probability of having hereditary BC have BRCA1 mutations,
selecting women with a long term survival among this population could increase the rate of positive analyses,
avoiding the use of expensive tests.
Background
The major breast cancer (BC) predisposing genes,
BRCA1 and BRCA2 were identified in 1994 and 1995,
respectively [1,2]. Unfortunately, the optimal clinical
approach to women who develop hereditary breast can-
cer remains incompletely defined. Studies of the out-
comes of women with BRCA1/BRCA2-related cancer
have yielded conflicting results. Several reports sug-
gested that women with germline mutations in BRCA1
are more likely to die from their disease than are
women with sporadic breast cancer [3-6], whereas
BRCA2 mutation carriers and non-mutation carriers
seem to share a similar prognosis [7,8]. The poor prog-
nosis in BRCA1 carriers may be consistent with the
histological characteristics usually described for BRCA1-
associated breast cancer, which show higher histologic
grade and cancers that are more often hormone recep-
tor-negative than sporadic breast cancer cases [9-12].
However, Bonadona et al. found no evidence for poorer
short-term survival in BRCA1 mutation carriers com-
pared with non-carriers in a prospective population-
based cohort [13]. Apart from a simple interest in the
epidemiological aspects of breast malignancy, knowledge
of the associated mortality is important to the families
of patients with BC and to clinicians and scientists
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involved in trying to improve the outcomes of breast
cancer. The results of a recent study in an Ashkenazi
Jewish population suggested that among the subgroup
of patients with BC carrying a BRCA1 mutation, those
who received chemotherapy had a better survival rate
compared with those who did not [8].
The primary aim of our study was to calculate disease
free survival (DFS) and overall survival (OS) of BC
patients at high risk (H) or intermediate slightly (IS)
increased risk based on family history and those without
a family history of breast cancer using the population
registered with the Breast Cancer Registry in Modena.
Previous studies were aimed at evaluating the outcome
in BRCA-positive and BRCA-negativepatients, but none
showed a significant survival difference between differ-
ent risk categories. In case of statistically significant dif-
ferences in OS between the three groups, a secondary
aim was to determine whether patients with a better
prognosis were BRCA1 mutation carriers, showing that
the outcome could be considered an indicator of BRCA1
inheritance. Additionally, we evaluated whether che-
motherapy could play a role in the prognosis of BRCA1
carriers, providing more benefit in this patient popula-
tion than in patients with sporadic breast cancer.
Methods
Patients
Patients included in our analysis were diagnosed
between 1988 and 2006 at the Department of Oncology
and Haematology in Modena. All newly-diagnosed,
biopsy-proven primary breast cancer patients were eval-
uated. The family history was collected and classified
according to the Modena criteria (without family his-
tory, IS increased risk, or H risk)[14] and a blood sam-
ple, preserved with EDTA, was obtained with informed
consent and frozen at -80°C for biological studies. On
the basis of the Modena criteria for familial risk,
patients who did not have any family history were con-
sidered to have sporadic breast cancer, patients with one
or two breast cancers at ≥ 40 years, without a first-
degree relationship, were considered at IS increased risk,
and patients with breast cancer at ≤ 35 years, three or
more breast cancers with a first-degree relationship, and
at least one case at ≤ 40 years or bilateral breast cancer
had a H risk of being hereditary.
All research regarding the identification, counselling,
genetic testing, and clinical data regarding individuals at
risk of developing breast cancer were ethically approved
by the Ethics Commitee of Modena (reference number
45/00).
Mutational analysis
In 1995, DNA started to be extracted from frozen whole
blood using the Invisorb Blood Universal kit (Invitek,
Berlin, Germany), amplified by PCR using primers speci-
fic for the coding sequence and exon-intron boundaries
of BRCA1, and analyzed by Direct Automated Sequen-
cing using an ABI Prism 3100 (Applied Biosystems, Fos-
ter City, CA). Subsequently, patients with breast cancer
provided consent for genetic testing that was completed
for each case.
Samples negative for BRCA1 mutations were tested for
BRCA1 rearrangements using the multiplex ligation-
dependent probe amplification assay (MRC Holland,
Amsterdam, The Netherlands) following the manufac-
turer’s protocol.
Statistical analysis
The c2 test was used to determine differences in clinico-
pathological features between groups. Survival curves
were estimated using the Kaplan-Meier method includ-
ing the log-rank test group comparison. Patients who
were BRCA1 carriers were matched with patients with
sporadic breast cancer from the Modena cancer registry.
This registry, initiated in 1988, covers an area with
approximately 650,000 inhabitants in Northern Italy. A
database with a total of 3858 cases of sporadic breast
cancer was used to find four matched controls for each
case and a randomized matches were assigned between
BRCA1 and patients with sporadic BC of the same age
at diagnosis (range, between 26 and 76 ± 4 years),
tumour grade (I, II, and III), and stage (I, II, and III).
Multivariate analyses of DFS and OS were conducted
using a proportional hazards Cox regression model. All
statistical analyses were done with SPSS, version 12.0
(SPSS Inc, Chicago, IL).
Results
Patient Characteristics
From January 1988 and December 2006, 5923 patients
were diagnosed with breast cancer. According to their
family history, 4912 were considered sporadic breast
cancers, 691 were at IS increased risk, and 320 were
considered H risk. The patients’ characteristics are
detailed in Table 1. The H risk group presented with a
medullary carcinoma histotype more frequently than the
other two groups (p < .0001). The H risk group was
more likely to have stage II disease than the sporadic
and IS increased risk groups (p < .0001), and to have a
significantly lower estrogen receptor (ER) and progester-
one receptor (PgR) expression levels (p < .0001) as mea-
sured by immunohistochemical analysis (clone 6F11,
Ventana, for ER; and clone 1E2, Ventana, for PgR) and
stained by Ventana Benchmark autostainer. The ER and
PgR receptor status was tested by evaluating the percen-
tage of nuclear immunoreactivity with respect to all the
nuclei in the neoplastic cells, independently of the stain-
ing intensity. No differences were seen in the Ki67 level
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between the groups (p = .17). The proportion of patients
who received adjuvant chemotherapy was greater in the
IS increased risk group than in the other two groups
(p < .0001). The most frequent chemotherapy strategy
was anthracycline-based followed by taxanes and the
CMF regimen. The most frequently used first line che-
motherapy regimen was platinum based, followed by a
CMF scheme. The proportion of patients who received
adjuvant hormone therapy was lower in the H risk group
than in the other two groups, according to the negative
hormonal receptor status (p < .0001).
Mutational Analysis
The BRCA1 mutational analysis was only performed in
patients belonging to the H and IS risk groups, with a
22.8% (73/320) and 1.0% (7/691) mutation rate, respec-
tively. In total, 80 patients were BRCA1 carriers.
Survival analysis
Overall, 5923 patients were followed until December
2006, resulting in a median follow-up time of 72
months. In all, 1302 deaths (1074 sporadic, 174 IS
increased risk, and 54 H risk) and 1137 relapses (884
sporadic, 186 IS increased risk, and 67 H risk) were
reported. The estimated 10-year overall survival rate was
82% for the H risk patients, 75% for the IS increased
risk group, and 73% for patients with sporadic breast
cancer (log-rank p < .0001; Fig. 1A). The estimated 10-
year DFS was 72% in the H risk group, 70% in the IS
increased risk group, and 75% in patients with sporadic
Table 1 Clinicopathological characteristics of patients according to familial risk group
Family Risk Group
No family history Intermediate-Slightly increased risk High Risk p
(n = 4912) (n = 691) (n = 320)
Characterics N° % N° % N° %
Histotype
Ductal 3936 80.1 565 81.8 251 78.4 NS
Lobular 606 12.3 83 12.0 44 13.7 NS
Tubular 93 1.9 13 1.9 2 0.6 NS
Colloid 64 1.3 10 1.4 0 0 NS
Medullary 26 0.5 6 0.9 13 4.1 < .0001
Other 187 3.9 14 2.0 10 3.2 NS
Stage
I 2322 47.3 312 45.1 141 44.1 NS
II 1546 31.5 255 36.9 127 39.7 < .0001
III 802 16.4 112 16.2 48 15.0 NS
IV 216 4.4 11 1.8 1 0.3 <.0001
X 23 0.5 1 0.1 3 0.9 NS
ER
Positive 3286 66.8 448 64.8 147 45.9 < .0001
Negative 757 15.4 139 20.2 149 46.6 < .0001
Unknown 869 17.8 103 15.0 24 7.5 < .0001
PgR
Positive 2796 56.9 408 59.1 135 42.2 < .0001
Negative 1109 22.5 173 25.0 162 50.6 < .0001
Unknown 1007 20.6 110 15.9 23 7.2 < .0001
Ki67
Low (0-19) 2523 51.4 383 55.4 185 57.8 NS
High (20-100) 1109 22.5 167 24.2 103 32.2 NS
Unknown 1007 20.6 141 20.4 32 10.0 NS
Chemotherapy
Yes 1851 37.7 350 50.7 106 33.1 < .0001
No 3061 62.3 341 49.3 214 66.9 < .0001
Hormone therapy
Yes 2804 57.1 380 55.0 106 33.1 < .0001
No 2108 42.9 311 45.0 214 66.9 < .0001
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor
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Figure 1 Overall survival and disease free survival according to risk group (A, C) and to BRCA1 status (B, D).
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breast cancer (log-rank p = .12; Fig. 1C). After the
genetic analysis, 80 patients were classified as BRCA1
carriers and 931 were considered BRCA negative. In the
BRCA1 carrier group, 8 deaths (5 caused by a second
tumour arising after breast cancer) and 13 relapses (6
local recurrences and 7 distant recurrences) were
reported, whereas in the BRCA negative group 220
deaths and 240 relapses occurred. The 10-year overall
survival rate was 77% for BRCA1 carriers, 77% for
BRCA-negative patients, and 73% for sporadic breast
cancer (log-rank p < .001; Fig. 1B). The 10-year DFS
was 75% in sporadic breast cancer, 70% in the BRCA-
negative patients, and 70% in the BRCA1 group (log-
rank p = .45; Fig. 1D).
The study group of 80 BRCA1 cases was compared
with 320 matched sporadic cases from the Modena can-
cer registry which were the same age, and had the same
tumour grade and stage. Results are shown in Fig. 2. A
statistically significant difference in OS was seen for
BRCA1 patients compared with sporadic BC (85% vs.
73%, respectively, p = .05).
According to the hormone receptor status, the hor-
mone receptor-negative patients in the H risk group
and the BRCA1 patients had a better OS (Fig. 3A, B)
while a hormone receptor-positive advantage was only
seen in the H risk group, but not in the BRCA1 group
(Fig. 3C, D).
Multivariate survival analysis according to prognostic
factors and chemotherapy
Of the 5923 patients, 5012 were included in multivariate
analyses, which included BRCA1 status, disease stage,
ER status, PgR status, grading, age, and chemotherapy.
The BRCA1 positive and negative status was a signifi-
cant independent factor for improved OS (HR = 0.29;
p = .002 and HR = 0.76; p = < .001, respectively) com-
pared with the sporadic breast cancer cases. Positive ER
and PgR status was associated with a better OS (HR =
0.82; p = .03 and HR = 0.79; p = .004, respectively).
Also, chemotherapy was an important factor in reducing
the mortality rate (HR = 0.68; p < .0001). Stage > I
(HR = 3.49; p < .0001) and grading III (HR = 1.39; p <
.0001) were significant factors for poorer OS. Younger
age (≤ 35 years) represented a risk factor for a shorter
OS, but the trend was not statistically significant. In a
model that included 2213 patients receiving chemother-
apy, BRCA1-positive status (HR = 0.38; p = .05) but not
BRCA1-negative status (HR = 0.97; p = .79) reduced the
mortality rate. Positive PgR status (HR = 0.76; p = .021)
was a favourable factor as was positive ER status (HR =
0.76; p = .083), but did not reach statistical significance.
Stage > I (HR = 3.55; p < .0001) and grading III (HR =
1.38; p < .0001) were factors statistically associated with
an increased risk of death. There was a similar but non
significant trend in age ≤ 35 years (HR = 1.15; p = .44).
Conversely, in a model without chemotherapy, the
BRCA1-positive status lost statistical significance in
reducing mortality (HR = 0.23; p = 0.056), whereas the
BRCA1-negative status maintained its favourable impact
(HR = 0.56; p < .0001). Also, positive ER (HR = 0.82,
p = .17) and PgR status (HR = 0.82; p = .08) and age
less than 35 years (HR = 0.95;p = .85) did not affect OS.
Finally, stage > 1 (HR = 3.43; p < .0001) and grading III
(HR = 1.39; p < .0001) were statistically associated with
an increased risk of death. Detailed results for multivari-
ate analysis are shown in Table 2.
In comparing BRCA1 patients who did or did not
receive chemotherapy, no difference was seen in terms
of OS (see Fig. 4), even if all the death events in the
treated group of patients were derived from second
tumours (4 cases).
Discussion
The results of this large analysis show that patients con-
sidered at H risk of being BRCA1 carriers had a better
OS than patients considered at IS increased risk or to
have sporadic breast cancer. This difference was also
maintained in BRCA1 carriers with respect to BRCA1-
negative and sporadic breast cancer patients. Notably,
91.2% (73/80) of BRCA1 carriers were identified in the
H risk group, and may explain the survival advantage in
this group of patients, even if other reasons may be
Figure 2 Probability of survival in 80 BRCA1 breast cancer
cases and 320 sporadic breast cancer controls matched for age
and tumour grade and stage, using Kaplan-Meier analysis.
There was a statistically significant difference between the two
groups (log-rank test, p = .05).
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Figure 3 Overall survival according to risk group in hormone receptor negative (A) and positive (C) patient subgroups, and according
to BRCA1 status in hormone receptor negative (B) and positive (D) patient subgroups.
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involved. Patients who know they are at high risk of
developing breast cancer may be more likely to partici-
pate in surveillance programs and start at a younger
age, receive an earlier diagnosis, and subsequently,
experience a better outcome.
One of the most important findings of our study was
that the survival difference was attributable, in a multi-
variate analysis, to the patient’s BRCA1 status and was
observed in patients treated with chemotherapy. This
finding is important when, as happens in a family cancer
centre like in ours, we are faced with a patient or a
healthy woman who has a family history of breast
cancer. By collecting all the information about indivi-
duals affected by breast cancer, very long-term survivors
can be identified by predicting a predisposition for being
a BRCA1-mutation carrier in the descendants. Further-
more, BRCA1 carriers may be more likely to be found
among women who have a high probability of hereditary
breast cancer and who have a long term survival. If
BRCA1 carriers could be identified through these char-
acteristics, the use of expensive tests could be avoided
and the rate of positive analyses increased.
Our study involves a very large number of Caucasian
patients with breast cancer (N = 5923) who were first
evaluated for their family history of breast cancer and
subsequently for BRCA1 status. The most common
weakness of previous studies includes the small number
of patients or selection bias, such as a retrospective ana-
lysis for BRCA1 status. Owing to the large number of
subjects, we could calculate OS differences between risk
groups, and even in subgroup analyses.
Unexpectedly, the survival difference according to H
risk and BRCA1 status was not related to the DFS. This
finding shows that the H risk and BRCA1 patients have
the same DFS as the other two groups, but seem to
respond better to chemotherapeutic agents. This finding
is in contrast with the results of Rennert et al. [8] who
showed an insignificant difference in OS between BRCA
carriers and non carriers and between BRCA1 carriers
and BRCA-negative patients treated with chemotherapy.
Our argument is that, in BRCA1 patients, 41% of
relapses were local recurrences, whereas in patients with
sporadic BC the local recurrence rate was 25%, and dis-
tant metastases accounted for 75%. Consequently, it is
Table 2 Cox’s proportional hazard regression models for
overall survival
Variable N° (%) HR p [95% CI]
All cases 5012 (85)
Sporadic 4172 (83) 1.00 - -
BRCA - 785 (16) 0.76 < .001 0.64 to 0.89
BRCA1+ 55 (1) 0.29 .002 0.13 to 0.62
stage > 1 2372 (47) 3.49 < .0001 3.01 to 4.04
Estrogen receptor
positive
4090 (82) 0.82 .03 0.69 to 0.98
Progesterone receptor
positive
3138 (64) 0.79 .004 0.67 to 0.93
Chemotherapy, yes 2213 (44) 0.68 < .0001 0.59 to 0.77
Age ≤ 35 199 (4) 1.12 .42 0.84 to 1.49
Grading III 1778 (35) 1.39 < .0001 1.22 to 1.58
Model with chemotherapy 2213 (44)
Sporadic 1780 (36) 1.00 - -
BRCA- 404 (8) 0.97 0.79 0.78 to 1.20
BRCA1+ 29 (2) 0.38 .05 0.14 to 0.99
Stage > I 1689 (76) 3.55 < .0001 2.65 to 4.76
Estrogen receptor
positive
1571 (71) 0.81 .083 0.65 to 1.02
Progesterone receptor
positive
1492 (67) 0.76 .021 0.61 to 0.96
Age ≤ 35 years 128 (6) 1.15 .44 0.81 to 1.62
Grading III 1116 (50) 1.38 < .0001 1.15 to 1.64
Model without
chemotherapy
2799 (56)
Sporadic 2392 (85) 1.00 - -
BRCA- 381 (14) 0.56 < .0001 0.43 to 0.73
BRCA1+ 26 (1) 0.23 .056 0.14 to 1.02
stage > I 951 (34) 3.43 < .0001 2.89 to 4.09
Estrogen receptor
positive
2519 (90) 0.82 .17 0.63 to 1.08
Progesterone receptor
positive
2298 (82) 0.82 .08 0.65 to 1.03
Age ≤ 35 71 (3) 0.95 .85 0.56 to 1.60
Grading III 662 (24) 1.39 < .0001 1.15 to 1.68
Abbreviations: HR, hazard ratio; CI, confidence interval
Figure 4 A comparison of the group of BRCA1 patients who
received or did not receive chemotherapy did not show any
difference in overall survival (log-rank test, p = .69).
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not surprising that a difference in OS was found and
could be explained by the use of alkylating agents, such
as platinum-derived drugs, in metastatic disease that are
well known to be more effective in BRCA-related
tumours [15]. Furthermore, since BRCA1 patients main-
tain a statistically significant OS advantage, even after
matching each case to four controls for age and tumour
grade and disease stage, this result is very important in
terms of its practical value, because all confounders
have been removed.
Robson et al [12] suggested that a BRCA1 mutation
was an independent predictor of breast cancer mortality
in a multivariate analysis of a group of women who did
not receive chemotherapy, but not in women who
received adjuvant chemotherapy.
In a multivariate analysis, we found that chemotherapy
is a prognostic factor for better survival in all patients
combined; furthermore, we found that a BRCA1-positive
status was an independent predictor for a better survival
in all patients and also in the subgroup of patients who
received chemotherapy, but not in patients who did not
receive chemotherapy. No differences are shown for
BRCA1 patients, independently of chemotherapy or not.
Also, this result might be explained by the fact that
deaths in the treated group of patients were all related
to a second tumour, while in the non treated group one
of three deaths was caused by breast cancer. In conclu-
sion, chemotherapy has a greater protective effect in
BRCA1 mutation carriers compared with patients who
are BRCA-negative and those with sporadic breast can-
cer. Furthermore, since BRCA1-related tumours are
more likely to be triple negative, the greatest advantage
was shown for ER-negative breast cancer, were che-
motherapy is the most active. Hence, increasing the
number of BRCA1 carriers identified by correctly select-
ing patients with a high probability of having hereditary
breast cancer through a 10-year survival analysis could
improve the benefit derived from specific chemotherapy
agents (i.e., alkylating or PARP-inhibitors).
In fact, the chemotherapy benefit is well known
because normal BRCA1 and BRCA2 proteins participate
with RAD51 in the repair of double-stranded DNA
breaks induced by DNA-damaging agents [16-19]. The
better prognosis could be due to the deficiency of the
BRCA proteins, which confer substantial cellular sensi-
tivity to the inhibition of poly (ADP-Ribose) polymerase
enzyme (PARP). This polymerase is a key enzyme in the
repair of single-stranded DNA damage via the base exci-
sion repair pathway. The loss of PARP activity in BRCA
mutant cells might lead to the persistence of DNA
lesions normally repaired by homologous recombination,
resulting in increased chromosome instability and pro-
grammed cell death specifically in tumour cells [20,21].
Therefore, because there is no functional protein within
the tumour cells, they lose their capacity to repair DNA
damage. This might be specifically pronounced for
drugs, such as cisplatin, acting through the induction of
DNA damage leading to cell death and to a better thera-
peutic response. In a small clinical study, Chappuis et al
[22] found a benefit in Ashkenazi Jews with locally
advanced breast cancer who were BRCA-positive and
treated with anthracycline-based chemotherapy regi-
mens. In this study, all patients received anthracycline-
based neoadjuvant chemotherapy, and 10 of 11 patients
with BRCA mutations had a clinical complete response
compared with only 8 of 27 BRCA-negative patients
with sporadic breast tumours. From this study, it was
inferred that tumours with BRCA1 mutations are highly
sensitive to anthracycline-based chemotherapy regimens.
In our study, patients were considered part of a hospi-
tal-based population and were not selected for age,
tumour stage, or treatment, which could influence survi-
val rates. We were successful in obtaining blood samples
from all patients and were able to genotype all the sam-
ples we received. The patients were followed for a med-
ian of 72 months. Treatment regimens were chosen on
the basis of disease staging. The Modena Cancer Registry
captures outcome data from almost all patients with can-
cer who are treated in the province. Data on pathological
diagnosis are verified by a pathologist, and incomplete
information is retrieved from medical records when pos-
sible. All patients were Caucasian, and it is possible that
the chemotherapy sensitivity can be associated with spe-
cific modifier genes not found in other populations.
Our study has a number of limitations. Tumour stage
and hormone receptor status were not routinely
recorded, particularly during the first period. Since we
tested only a subpopulation of patients with a positive
family history of breast cancer, it is possible that some
hereditary cases were misclassified; but we found that
only 1% of mutations occurred in the IS increased risk
group suggesting that the number of BRCA1 carriers in
the sporadic group would be very low. Since we identi-
fied only 80 mutation carriers, the subgroup analysis
relied on a small number of subjects.
In conclusion, our study is the first to evaluate a rela-
tionship between familial risk of breast cancer and a
genetic assessment in terms of DFS and OS. We pro-
pose that the increased survival associated with a family
history of breast cancer, suggesting hereditary breast
cancer according to the Modena criteria, should be con-
sidered with respect to BRCA1 analysis as a predictor of
mutations. We feel that randomized studies need to be
designed to further address the relationship between
BRCA1 mutations and sensitivity to chemotherapy, and
further clinical investigations are required to determine
whether the BRCA1 status can be used to predict treat-
ment outcomes.
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Conclusions
In conclusion, our data show that patients belonging to
a population with a high probability of being BRCA1
carriers have a better prognosis than other risk groups,
and this could be considered an indicator of BRCA1
inheritance. This paper provides, for the first time, evi-
dence-based proof that women at high risk of being
BRCA1 carriers have a favorable prognosis after 10 years
follow-up.
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